Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy

Area of Science:

• Pulmonary Medicine
• Nanotechnology
• Pharmaceutics

Background:

• Efficient drug delivery to the lungs is a significant challenge.
• Dry powder aerosols offer advantages over liquid formulations, including stability and ease of use.
• Optimizing particle size (1-5 micrometers) is crucial for lung deposition, while nanoparticles can enhance dissolution rates for poorly soluble drugs.

Purpose of the Study:

• To develop nifedipine nanoparticle agglomerates for pulmonary delivery.
• To improve the dissolution rate of the poorly soluble hypertension drug, nifedipine.
• To assess the aerodynamic performance of the formulated nanoparticles for lung deposition.

Main Methods:

• Nifedipine nanoparticles were co-precipitated with stearic acid to create a negatively charged colloid.
• Sodium chloride was used to destabilize the colloids, inducing controlled agglomeration of nanoparticles.
• Cascade impaction was employed to evaluate the aerodynamic properties of the resulting powders.

Main Results:

• The formulated nifedipine nanoparticle agglomerates demonstrated suitable aerodynamic performance for pulmonary delivery.
• The agglomerated nanoparticles exhibited enhanced dissolution rates compared to non-agglomerated forms.
• The study confirmed the potential of this formulation strategy for poorly water-soluble drugs.

Conclusions:

• Nifedipine nanoparticle agglomerates are well-suited for pulmonary drug delivery.
• This formulation approach enhances the dissolution of poorly soluble drugs, offering a viable strategy for pulmonary medicines.
• Nifedipine powders present a promising therapeutic option for treating pulmonary hypertension.